| Tyrosyl phosphorylation of KRAS stalls GTPase cycle via alteration of switch I and II conformation Y Kano, T Gebregiworgis, CB Marshall, N Radulovich, BPK Poon, ... Nature communications 10 (1), 224, 2019 | 91 | 2019 |
| NRAS Status Determines Sensitivity to SHP2 Inhibitor Combination Therapies Targeting the RAS–MAPK Pathway in Neuroblastoma I Valencia-Sama, Y Ladumor, L Kee, T Adderley, G Christopher, ... Cancer Research 80 (16), 3413-3423, 2020 | 53 | 2020 |
| Hippo component TAZ functions as a co-repressor and negatively regulates ΔNp63 transcription through TEA domain (TEAD) transcription factor I Valencia-Sama, Y Zhao, D Lai, HJJ van Rensburg, Y Hao, X Yang Journal of Biological Chemistry 290 (27), 16906-16917, 2015 | 46 | 2015 |
| The Q61H mutation decouples KRAS from upstream regulation and renders cancer cells resistant to SHP2 inhibitors T Gebregiworgis, Y Kano, J St-Germain, N Radulovich, ML Udaskin, ... Nature communications 12 (1), 6274, 2021 | 31 | 2021 |
| Combination mTOR and SHP2 inhibitor treatment of lymphatic malformation endothelial cells JK Wolter, I Valencia-Sama, AJ Osborn, EJ Propst, MS Irwin, B Papsin, ... Microvascular Research 143, 104397, 2022 | 4 | 2022 |
| Vitamin D receptor activation attenuates hippo pathway effectors and cell survival in metastatic neuroblastoma Y Ladumor, BKA Seong, R Hallett, I Valencia-Sama, T Adderley, Y Wang, ... Molecular Cancer Research 20 (6), 895-908, 2022 | 4 | 2022 |
| SHP2 inhibition with TNO155 increases efficacy and overcomes resistance of ALK inhibitors in neuroblastoma I Valencia-Sama, L Kee, G Christopher, M Ohh, M Layeghifard, A Shlien, ... Cancer Research Communications 3 (12), 2608-2622, 2023 | | 2023 |
| SHP2 INHIBITOR TNO155 SYNERGIZES WITH ALK INHIBITORS IN ALK-DRIVEN NEUROBLASTOMA MODELS I Valencia-Sama, L Kee, G Christopher, M Ohh, M Hayes, MS Irwin, ... Clinical cancer research 3 (12), 2608-2622, 2023 | | 2023 |
| Targeting SHP2 and RAS MAPK pathway in neuroblastoma I Valencia-Sama, T Adderley, L Kee, G Christopher, Y Kano, M Ohh, ... Cancer Research 79 (13_Supplement), 3123-3123, 2019 | | 2019 |
| Hippo component TAZ functions as a co-repressor and negatively regulates ANp63 transcription through TEAD I Valencia-Sama, Y Zhao, D Lai, HJJ van Rensburg, Y Hao, X Yang | | 2015 |
| Identification and characterization of ΔNp63 as a novel transcriptional target negatively regulated by TAZ in mammary tumorigenesis I Valencia Sama | | 2014 |
| SHP2 Inhibition as a Therapeutic Strategy to Target High-risk Neuroblastoma IA Valencia Sama | | |
